Primary outcome
Results for primary and secondary endpoints in each study are summarized in table 3. There was no difference in mortality at follow-up between patients who underwent MI and MS (IRR: 0.98 [95% CI: 0.25­–3.82], p = 0.98) and the groups were homogeneous (χ2 1.5, I2 0%, p=0.91). Similarly there was no difference in tumor recurrence (IRR: 1.13[0.26-4.88], p=0.87) with low heterogeneity (p=0.9) (figure 2 A/B ). The overall mean follow-up duration was 33.31 months (range 3.7 -56 months).